Patient Health Questionnaire – Depression (PHQ-9)

1. Abstract

The Patient Health Questionnaire – Depression (PHQ-9) is a globally established, nine-item self-report instrument engineered to operationalize the diagnostic criteria for major depressive disorder (MDD) delineated in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV and DSM-5). Originating from the broader Patient Health Questionnaire (PHQ) framework developed by Drs. Robert L. Spitzer, Janet B. W. Williams, and Kurt Kroenke, the PHQ-9 serves a dual clinical and psychometric purpose: establishing provisional categorical diagnoses of depressive episodes and quantifying continuous depressive symptom severity. Each item captures one of the nine canonical DSM criteria on a four-point ordinal frequency scale ranging from 0 (“Not at all”) to 3 (“Nearly every day”) over a two-week recall window, yielding a composite severity score between 0 and 27.

Psychometrically, the PHQ-9 demonstrates exceptional internal consistency across heterogeneous populations, with Cronbach’s alpha coefficients typically ranging from .86 to .89 in primary care and medical settings, and test-retest reliability coefficients exceeding .84. Criterion-related validity assessments against structured psychiatric interviews—such as the Structured Clinical Interview for DSM (SCID)—consistently yield sensitivity and specificity values of approximately 88% at the conventional cut-off score of 10. Factor analytic investigations reveal robust unidimensionality supporting a unified depression latent construct, alongside well-documented bifactor configurations comprising somatic and cognitive-affective sub-dimensions. The instrument’s non-proprietary status, brevity, robust psychometric properties, and responsiveness to therapeutic change have solidified its status as an international benchmark for depression screening, epidemiological research, and measurement-based care.

2. Keywords

Patient Health Questionnaire, PHQ-9, Major Depressive Disorder, Psychometrics, Depression Screening, Construct Validity, Measurement-Based Care, Primary Care Psychiatry, Diagnostic Accuracy, Factor Structure

3. Authors

The Patient Health Questionnaire – Depression (PHQ-9) was developed by a distinguished interdisciplinary consortium of psychiatric epidemiologists and primary care researchers led by:

• Robert L. Spitzer, M.D. — Professor of Psychiatry at Columbia University and Chief of New York State Psychiatric Institute’s Biometrics Research Department. Dr. Spitzer was the architect of modern psychiatric nosology, having chaired the DSM-III task force that transformed psychiatric classification into an operationalized, criterion-based discipline.
• Janet B. W. Williams, D.S.W. — Professor of Clinical Psychiatric Social Work in Psychiatry at Columbia University College of Physicians and Surgeons, renowned for her methodological contributions to structured clinical interviewing and diagnostic reliability assessment.
• Kurt Kroenke, M.D., MACP — Professor of Medicine at Indiana University School of Medicine and Senior Research Scientist at the Regenstrief Institute. Dr. Kroenke is a world authority on symptom science, somatic symptom disorders, and measurement-based mental health integration in primary medical care.

The instrument was formulated with collaboration from colleagues at Duke University and the University of North Carolina, funded in part by an educational grant from Pfizer Inc. Institutional correspondence regarding the instrument’s theoretical lineage historically traces to the Department of Psychiatry, Columbia University, New York, NY, and the Regenstrief Institute, Indianapolis, IN.

4. Purpose

The primary clinical and epidemiological objective of the PHQ-9 is to provide an efficient, psychometrically sound, self-administered mechanism for the identification, categorization, and longitudinal monitoring of major depression across clinical and research environments. Prior to the development of the PHQ system, diagnostic screening for psychiatric disorders in non-psychiatric settings relied heavily on lengthy clinician-administered interviews, such as the Primary Care Evaluation of Mental Disorders (PRIME-MD), or general symptom inventories like the Beck Depression Inventory (BDI) and the Center for Epidemiologic Studies Depression Scale (CES-D). While psychometrically valuable, these instruments were either too burdensome for fast-paced medical clinics or lacked direct one-to-one congruence with formal diagnostic classifications.

The PHQ-9 addresses this structural gap through a twofold operational purpose:

• Categorical Diagnostic Algorithm: The instrument can be scored using an algorithmic framework mirroring the DSM-IV/DSM-5 diagnostic logic. A probable major depressive episode is identified if at least 5 of the 9 symptoms are endorsed as present for “More than half the days” (score ≥ 2) during the preceding two weeks—with Item 9 (“thoughts of death or self-harm”) counted if endorsed at all (score ≥ 1)—provided that at least one of the endorsed symptoms represents a cardinal diagnostic criterion: Item 1 (anhedonia) or Item 2 (depressed mood).
• Continuous Dimensional Severity Metric: The nine items can simply be summed to yield a continuous dimensional score between 0 and 27. This enables clinicians to track symptom trajectory, titrate psychopharmacological or psychotherapeutic interventions, detect early signs of clinical relapse, and quantify the Minimal Clinically Important Difference (MCID), conventionally identified as a 5-point shift in total score.

Beyond routine outpatient medical settings, the PHQ-9 is deployed in specialized oncology, cardiology, neurology, and obstetric-gynecologic care, where somatic symptoms of medical illness frequently confound standard psychological evaluations. In contemporary clinical trials, the PHQ-9 functions as a primary or key secondary outcome endpoint, facilitating standardized cross-study meta-analyses and health economics evaluations.

5. Psychological Construct

The psychological construct evaluated by the PHQ-9 is Major Depressive Episode Severity, conceptualized in strict alignment with the nosological criteria of the American Psychiatric Association’s diagnostic manuals. Within this framework, major depression is operationalized as a multidimensional affective, cognitive, and neurovegetative syndrome characterized by sustained deficits in emotional regulation, reward processing, physical vitality, and cognitive executive control. The scale systematically measures nine distinct behavioral and phenomenological components:

1. Anhedonia (Item 1: Little interest or pleasure in doing things)

Anhedonia represents a core cardinal feature of melancholic and major depressive pathology. Psychometrically, this item captures deficits in consummatory and anticipatory pleasure, motivation, and hedonic tone, which stem neurobiologically from altered dopaminergic signaling within mesolimbic reward circuits.

2. Depressed Mood (Item 2: Feeling down, depressed, or hopeless)

This item captures the affective core of depression, encompassing profound dysphoria, negative affective valence, subjective sorrow, and demoralization. Hopelessness, embedded directly into this item, is a recognized cognitive vulnerability factor strongly linked with depressive chronicity and downstream suicidal behavior.

3. Sleep Dysregulation (Item 3: Trouble falling or staying asleep, or sleeping too much)

Depressive neurobiology frequently disrupts circadian architecture. This bidirectional item captures sleep onset latency, sleep maintenance insomnia, terminal early-morning awakening, as well as hypersomnia—a frequent feature in atypical depressive presentations.

4. Anergia and Fatigue (Item 4: Feeling tired or having little energy)

This somatic dimension evaluates generalized vitality depletion, subjective fatigue, physical exhaustion, and loss of sustained stamina. It represents one of the most pervasive symptoms encountered in medical populations, frequently cross-loading with chronic medical illness.

5. Appetite and Weight Disturbances (Item 5: Poor appetite or overeating)

Like the sleep item, this criterion accounts for bidirectional somatic dysregulation. It measures hypophagia (appetite suppression, often culminating in clinically significant weight loss) as well as hyperphagia (comfort eating or carbohydrate craving), reflecting central metabolic and neuroendocrine perturbations.

6. Negative Self-Concept and Worthlessness (Item 6: Feeling bad about yourself)

Reflecting cognitive formulations of depression, this item operationalizes profound guilt, internalized failure, low self-efficacy, and excessive self-reproach. It corresponds to Aaron Beck’s negative cognitive triad regarding the self, representing distorted depressogenic self-schemas.

7. Executive and Cognitive Dysregulation (Item 7: Trouble concentrating on things)

Depression involves marked impairments in working memory, sustained attention, and processing speed. Item 7 evaluates subjective cognitive inefficiencies manifested in everyday activities, such as reading or tracking media presentations, which correlate with prefrontal hypofunction.

8. Psychomotor Alterations (Item 8: Moving or speaking slowly / being fidgety or restless)

This item evaluates observable psychomotor retardation (bradykinesia, speech latency, blunted motor activity) versus psychomotor agitation (motor restlessness, hand-wringing, inability to sit still). It specifically highlights manifestations noticeable to external observers, tapping into objective neurobiological inhibition or disinhibition.

9. Suicidal Ideation and Death Wishes (Item 9: Thoughts that you would be better off dead)

This critical safety item assesses morbid ideation, ranging from passive death wishes (e.g., preference for non-existence) to active thoughts of self-directed violence and autolytic intent. It functions as an indispensable red-flag metric mandating immediate clinical risk triage.

6. Theoretical Framework

The PHQ-9 is grounded at the intersection of neo-Kraepelinian psychiatric nosology, cognitive-behavioral theories of depression, and psychometric measurement theory.

Nosological Operationalism

The foundational framework derives from the diagnostic revolution initiated by the Feighner Criteria (1972) and the Research Diagnostic Criteria (RDC), which culminated in the DSM-III (1980) and DSM-IV (1994). This paradigm posits that mental disorders can be reliably differentiated via explicit, operationalized criteria evaluating objective symptom clusters over defined time intervals. By mapping its nine items directly onto the polythetic diagnostic criteria of MDD, the PHQ-9 established an unprecedented correspondence between an epidemiologic self-report questionnaire and formal psychiatric classification.

Cognitive Triad and Reward Deficit Models

Beyond formal classification, the PHQ-9 draws theoretical validity from Beck’s cognitive theory of depression. Beck posited that depression is characterized by systemic cognitive distortions: negative views of the self (captured by Item 6), the world/environment (Item 1 and Item 2), and the future (hopelessness in Item 2, suicidality in Item 9). Simultaneously, behavioral activation theories highlight anhedonia (Item 1) as a functional consequence of reduced response-contingent positive reinforcement, leading to avoidance behaviors, reduced activity, and escalating depressive withdrawal.

Latent Trait and Psychometric Paradigms

From a psychometric perspective, the PHQ-9 is formulated under both Classical Test Theory (CTT) and Item Response Theory (IRT). Under the CTT model, the nine items are considered parallel manifestations of a single, continuous, underlying latent construct: depressive severity. IRT analyses, particularly Samejima’s Graded Response Model (GRM), show that the items possess high discrimination parameters (α parameters often exceeding 1.5 to 2.5), meaning each item effectively differentiates individuals along the depressive severity continuum (θ continuum), particularly between mild, moderate, and severe clinical states.

7. Validity

The psychometric validity of the PHQ-9 has been established across clinical environments, demographic strata, and international linguistic contexts.

Criterion-Related and Diagnostic Validity

The landmark validation study conducted by Kroenke, Spitzer, and Williams (2001) assessed 6,000 adult patients across primary care and obstetrics-gynecology clinics. Criterion validity was evaluated against independent, blind structured psychiatric interviews administered by mental health professionals in a sub-sample of 580 participants. Using the clinical interview as the gold standard:

• A cut-off score of 10 or higher yielded a sensitivity of 88% and a specificity of 88% for major depressive disorder.
• The area under the Receiver Operating Characteristic (ROC) curve was extraordinarily high, ranging from .92 to .95 across multiple validation cohorts.
• In an individual participant data meta-analysis by Levis et al. (2019) encompassing 58 studies and 17,357 patients, a cut-off score of 10 exhibited an overall pooled sensitivity of .88 (95% CI: .85–.91) and a specificity of .85 (95% CI: .82–.88), corroborating Kroenke et al.’s original parameters.

Construct, Convergent, and Discriminant Validity

Construct validity is evidenced through strong convergent correlations between the PHQ-9 and established depression inventories:

• Correlations with the Beck Depression Inventory-II (BDI-II) typically range from r = .73 to .84.
• Correlations with the clinician-administered Hamilton Depression Rating Scale (HAM-D) range from r = .71 to .80.
• Correlations with the General Anxiety Disorder-7 (GAD-7) range between r = .65 and .75, demonstrating expected comorbidity while maintaining distinction through higher within-construct factor loadings.

Discriminant validity is supported by its relationship with physical health markers. While somatic symptoms (fatigue, sleep disturbance) can overlap with physical diseases, the cognitive-affective items of the PHQ-9 reliably dissociate depression from underlying somatic pathology in populations with chronic illness, such as end-stage renal disease, diabetes, coronary artery disease, and stroke. Moreover, strong associations exist between higher PHQ-9 scores and functional impairment measures, including the Medical Outcomes Study Short-Form (SF-20 / SF-36) physical and social functioning scales, healthcare utilization metrics, and documented disability days.

8. Reliability

The PHQ-9 demonstrates exceptional structural reliability, minimal measurement error, and high temporal stability across varied settings.

Internal Consistency

Internal consistency reflects the extent to which the nine items measure the same underlying construct. Across multiple validation investigations:

• In the original 6,000-patient primary care sample (Kroenke et al., 2001), Cronbach’s α was .89 in primary care clinics and .86 in obstetrics-gynecology clinics.
• Subsequent studies across inpatient medical, oncological, and psychiatric services report Cronbach’s α coefficients consistently between .85 and .92.
• Calculations of McDonald’s ω (omega total) routinely match or exceed .88, confirming robust composite reliability without relying on the restrictive tau-equivalence assumptions of Cronbach’s alpha.

Test-Retest Stability

Test-retest reliability reflects the stability of scores over time when clinical change has not occurred. Kroenke et al. (2001) administered the PHQ-9 in-person followed by a repeat administration via telephone within a 48-hour interval among 580 patients, yielding an intraclass correlation coefficient of r = .84. Similar short-term evaluations (retest windows of 1 to 7 days) report test-retest coefficients spanning .81 to .89, demonstrating that the instrument is resistant to transient day-to-day noise while remaining sensitive to true clinical evolution over multi-week intervals.

Standard Error of Measurement and Detectable Change

The Standard Error of Measurement (SEM) of the PHQ-9 is approximately 1.5 to 1.9 points across representative clinical populations. Based on this SEM profile, the Minimal Detectable Change (MDC) at a 95% confidence level is calculated at approximately 4.2 to 5.2 points. This provides empirical justification for the widely recognized clinical benchmark that a change of 5 points or more reflects genuine, statistically meaningful improvement or deterioration beyond measurement error.

9. Factor Analysis

The structural dimensionality of the PHQ-9 has generated an extensive psychometric literature, addressing debates regarding unidimensionality versus multidimensionality.

Exploratory and Confirmatory Factor Analyses

In the original validation studies, Exploratory Factor Analysis (EFA) demonstrated that all nine items loaded heavily on a single dominant factor accounting for over 50% to 60% of the total variance, with factor loadings ranging from .55 to .79. This finding supported treating the PHQ-9 as an essentially unidimensional scale. Subsequent Confirmatory Factor Analyses (CFA) across diverse international cohorts, however, have evaluated three competing structural models:

1. Unidimensional Model: A single general depression latent factor directly driving variance across all 9 items.
2. Two-Factor Correlated Model: Dividing the scale into a Cognitive-Affective factor (Items 1, 2, 6, 7, and 9) and a Somatic/Neurovegetative factor (Items 3, 4, 5, and 8).
3. Bifactor Model: A dominant, overarching General Depression factor that captures common variance across all items, alongside two independent, orthogonal group factors (Somatic and Cognitive-Affective).

While the bifactor model frequently demonstrates superior statistical fit indices, bifactor indices such as the Explained Common Variance (ECV ≥ .80) and Omega Hierarchical (ωh ≥ .85) confirm that the vast majority of reliable variance across the scale is driven by the general depression factor. Consequently, psychometricians and clinical consensus strongly support summing all nine items into a single composite severity index for practical diagnostic and monitoring applications.

10. Instrument / Measurement Tool

• Formal Tool Name: Patient Health Questionnaire – Depression (PHQ-9)
• Instrument Type: Standardized self-administered psychiatric rating scale / patient-reported outcome measure (PROM)
• Construct Assessed: Depressive episode presence and continuous symptom severity according to DSM-IV and DSM-5 criteria
• Total Number of Diagnostic Items: 9 operational items (plus an optional supplementary functional impairment item)
• Recall Window: Preceding 2 weeks (“Over the last 2 weeks…”)
• Response Format: 4-point ordinal Likert-type frequency scale:
  • 0 = Not at all
  • 1 = Several days
  • 2 = More than half the days
  • 3 = Nearly every day
• Total Score Range: 0 to 27 points
• Scoring and Clinical Severity Stratification:
  • 0 to 4: Minimal or no depression (monitoring; generally no clinical intervention required)
  • 5 to 9: Mild depression (watchful waiting; psychoeducation; reassessment within 1 to 3 months)
  • 10 to 14: Moderate depression (treatment plan initiation; consider psychotherapy and/or pharmacotherapy)
  • 15 to 19: Moderately severe depression (active treatment indicated with pharmacotherapy, psychotherapy, or combination)
  • 20 to 27: Severe depression (immediate active multi-modal treatment; psychiatric consultation; specialized safety review)
• Algorithmic Diagnostic Logic: Provisional diagnosis of Major Depressive Disorder is made if ≥ 5 of the 9 items are endorsed at a level of ≥ 2 (“More than half the days”), with Item 9 counted if endorsed ≥ 1, provided that at least one of the positive items is Item 1 or Item 2. Other Depressive Disorder is suggested if 2 to 4 items meet these thresholds.
• Completion Time: Approximately 2 to 3 minutes
• Reading Level: 5th to 6th-grade readability level (Flesch-Kincaid Grade Level ~ 5.4), ensuring accessible completion across broad general populations.

11. Permissions & Fee and Test Year

The Patient Health Questionnaire – Depression (PHQ-9) was published in 2001 by Drs. Robert L. Spitzer, Janet B. W. Williams, and Kurt Kroenke. Although the initial development was supported by an educational grant from Pfizer Inc., the copyright holders explicitly placed the PHQ-9 and its derivative PHQ instruments into the public domain.

Licensing and Fee Structure:

• No Fees: The PHQ-9 is entirely free of royalty fees, user license charges, or per-administration payments.
• No Prior Written Permission Required: Clinicians, healthcare organizations, government entities, and academic researchers may reproduce, distribute, translate, and digitize the PHQ-9 into electronic health record (EHR) systems without seeking formal permission from the authors or corporate sponsors.
• Permitted Uses: Routine clinical practice, commercial and non-commercial clinical trials, public health screening initiatives, and institutional research. Modifications that alter the item wording or response scales are strongly discouraged to preserve established psychometric properties.
• Official Repository: Standardized translations in more than 80 languages are accessible via public medical archives and the official PHQ Screeners portal.

12. References

• American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). American Psychiatric Association. https://doi.org/10.1176/ajp.152.8.1228
• Gilbody, S., Richards, D., Brealey, S., & Hewitt, C. (2007). Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): A diagnostic meta-analysis. Journal of General Internal Medicine, 22(11), 1596–1602. https://doi.org/10.1007/s11606-007-0333-y
• Huang, F. Y., Chung, H., Kroenke, K., Delucchi, K. L., & Spitzer, R. L. (2006). Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. Journal of General Internal Medicine, 21(6), 547–552. https://doi.org/10.1111/j.1525-1497.2006.00409.x
• Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x
• Levis, B., Benedetti, A., & Thombs, B. D. (2019). Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: An individual participant data meta-analysis. BMJ, 365, l1476. https://doi.org/10.1136/bmj.l1476
• Löwe, B., Unützer, J., Callahan, C. M., Perkins, A. J., & Kroenke, K. (2004). Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Medical Care, 42(12), 1194–1201. https://doi.org/10.1097/00005650-200412000-00006
• Manea, L., Gilbody, S., & McMillan, D. (2012). Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): A meta-analysis. Canadian Medical Association Journal, 184(3), E191–E196. https://doi.org/10.1503/cmaj.110829
• Spitzer, R. L., Kroenke, K., & Williams, J. B. W. (1999). Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. JAMA, 282(18), 1737–1744. https://doi.org/10.1001/jama.282.18.1737
• Wittkampf, K. A., Naeije, L., Schene, A. H., Huyser, J., & van Weert, H. C. (2007). Diagnostic accuracy of the mood module of the Patient Health Questionnaire: A systematic review. General Hospital Psychiatry, 29(5), 388–395. https://doi.org/10.1016/j.genhosppsych.2007.06.004

13. Items of the Scale (Questionnaire)